References
- Tamhane UU, Gurm HS. The chimeric monoclonal antibody abciximab: A systematic review of its safety in contemporary practice. Expert Opin Drug Saf 2008;7:809–819
- Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, Simoons ML, Califf RM. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75–83
- Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809–813
- Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Occurrence and clinical significance of trombocytopenia in a population undergoing high-risk percutaneous coronary revascularizatiCon. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. JACC 1998;32:311–319
- Coller BS. Monitoring platelet GP IIb/IIIa (corrected) antagonist therapy. Circulation 1997;96:3828–3832
- Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74–80
- De Caterina R, Zimarino M. Understanding the complexity of abciximab-related thrombocytopenia. Thromb Haemost 2010;103:484–486
- Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013;27:137–145
- Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004;2:985–992
- Webb GJ, Swinburn JM, Grech H. Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration. Platelets 2011;22:302–304
- Trapolin G, Savonitto S, Merlini PA, Caimi MT, Klugmann S. Delayed profound thrombocytopenia after abciximab administration for coronary stenting in acute coronary syndrome. Case reports and review of the literature. Ital Heart J 2005;6:647–651
- Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999–3054
- Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: Clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997;52:183–189